Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research
Methods: Azide motifs are anchored on the CAR-T cell surface via the intrinsic glycometabolism of exogenous azide-glucose, serving as an artificial ligand for imaging probes binding, confirmed by flow cytometry and confocal laser microscopy. In vitro activity and cytotoxicity of the chemically engineered anti-CD19-CAR-T (denoted as N3-CART) cells were determined. Then, N3-CART cells were intravenously infused into NOD-scid-IL2Rγnull (NSG) mice subcutaneously engrafted with Raji-luc cells. The feasibility of monitoring proliferation profiles and tracking N3-CART was verified by introducing the complementary functional moiety dibenzocyclooctyl (DBCO)-conjugated near-infrared fluorescence (NIRF) and nuclide probes (eg. DBCO-ICG and DBCO-DOTA-68Ga) into the mice, and the NIRF and positron emission tomography (PET) imaging were performed. In addition, the pharmacodynamics and pharmacokinetics of the N3-CART cells in mouse subcutaneous lymphoma models were simultaneously assessed using bioluminescence imaging and DBCO-DOTA-68Ga PET imaging.
Results: The azide labeling based on biological orthogonal chemistry would not affect the activity and killing function of anti-CD19-CAR-T cells in vitro. We achieved dynamic tracking of them by NIRF in vivo for two weeks, and PET images revealed that the uptakes of in CD19+ Raji subcutaneous tumors showed an increasing tendency from 30 min to 120 h p.i. after administration of N3-CART cells. It confirmed that the N3-CART cells could effectively inhibit the growth of Raji hematologic subcutaneous tumors.
Conclusion: This study presents a novel approach utilizing bioorthogonal labeling technology for imaging of CAR-T cells. We achieved dual-modal, non-invasive and dynamic tracking of CAR-T cells, providing a comprehensive view of their biodistribution and kinetics of infiltration within the body. This method provides a new means for monitoring and optimizing CAR-T therapy and is expected to further advance the field of CAR-T cell therapy.
Disclosures: No relevant conflicts of interest to declare.